Search Follow us


CollPlant’s Q317 marked continued commercial progress and increasing interest in its plant-based recombinant human collagen (rhCollagen) based technology. It announced multiple sales of its bioInk product for 3D tissue printing to a major biotechnology company and a major medical device company, which is very encouraging and potentially validating. Additionally, it expanded its commercial footprint for VergenixFG to Greece and Cyprus with a new distribution deal.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs